These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26164583)

  • 21. Omalizumab for hypersensitive reaction to seminal plasma: A case report.
    Burguete-Cabanas MT; Fajardo-Ramirez OR; Yesaki R; Estrada-Maganas R; Salazar-Meza S; Rios-Chavez O; Meester I; Salas-Alanis JC
    Allergol Int; 2018 Apr; 67(2):278-279. PubMed ID: 28821383
    [No Abstract]   [Full Text] [Related]  

  • 22. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
    Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
    Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
    [No Abstract]   [Full Text] [Related]  

  • 23. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
    Heffler E; Fichera S; Nicolosi G; Crimi N
    J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
    [No Abstract]   [Full Text] [Related]  

  • 24. Omalizumab.
    Easthope S; Jarvis B
    Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab.
    Kishimoto I; Kambe N; Ly NTM; Nguyen CTH; Okamoto H
    Allergol Int; 2019 Jul; 68(3):388-390. PubMed ID: 30792119
    [No Abstract]   [Full Text] [Related]  

  • 26. Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.
    Faisant C; Du Thanh A; Mansard C; Deroux A; Boccon-Gibod I; Bouillet L
    J Clin Immunol; 2017 Jan; 37(1):80-84. PubMed ID: 27826875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H
    J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Goldstein S; Gabriel S; Kianifard F; Ortiz B; Skoner DP
    Ann Allergy Asthma Immunol; 2017 Apr; 118(4):500-504. PubMed ID: 28390587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical option of omalizumab on refractory vasospastic angina with asthma and eosinophilic chronic rhinosinusitis.
    Hamada S; Tatsumi S; Taniguchi T; Yasuba H
    J Allergy Clin Immunol Pract; 2016; 4(4):753-5. PubMed ID: 27017534
    [No Abstract]   [Full Text] [Related]  

  • 30. Biologics in Chronic Urticaria.
    Bulkhi A; Cooke AJ; Casale TB
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):95-112. PubMed ID: 27886913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatologic uses of omalizumabtitle.
    Chia JC; Mydlarski PR
    J Dermatolog Treat; 2017 Jun; 28(4):332-337. PubMed ID: 27759482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
    Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
    [No Abstract]   [Full Text] [Related]  

  • 33. The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.
    Bartuzi Z; Bodzenta-Łukaszyk A; Kuna P; Kupryś-Lipińska I; Niżankowska-Mogilnicka E; Samoliński B
    Pneumonol Alergol Pol; 2015; 83(4):335-8. PubMed ID: 26166795
    [No Abstract]   [Full Text] [Related]  

  • 34. Omalizumab for chronic spontaneous urticaria: a boon for sufferers, but there are unanswered questions.
    Greaves MW
    Br J Dermatol; 2015 Aug; 173(2):321. PubMed ID: 26346076
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining Omalizumab with Another Biotherapy.
    Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
    Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
    [No Abstract]   [Full Text] [Related]  

  • 37. Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
    Bongiorno MR; Crimi N; Corrao S; Allotta A; Arena A; Brusca I; Heffler E; Malara G; Milioto M; Pistone G; Porto M; Raia E; Valenti G
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):703-707. PubMed ID: 27720581
    [No Abstract]   [Full Text] [Related]  

  • 38. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
    Aksu K; Kurt E
    Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 40. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.